Immune safety challenges facing the preclinical assessment and clinical progression of cell therapies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Stephanie M,Bates

第一单位： Safety Innovation, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

作者： Stephanie M,Bates ^[1] ; Kelly V,Evans ^[1] ; Louise,Delsing ^[2] ; Ryan,Wong ^[3] ; Georgina,Cornish ^[4] ; Mahnoush,Bahjat ^[5]

作者单位： Safety Innovation, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK. ^[1] Cell and Gene Therapy Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. ^[2] Cell and Gene Therapy Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK. ^[3] Oncology Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK. ^[4] Safety Innovation, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: mahnoush.bahjat@astrazeneca.com. ^[5]

关键词 Adverse immune response CAR-T Cell therapy Drug development Immunotherapy Safety

主题词人类(Humans);动物(Animals)

DOI 10.1016/j.drudis.2024.104239

PMID 39521331

发布时间 2024-12-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交